Key result
This review discusses the theoretical risks and benefits of drug-eluting stents for ST-elevation acute myocardial infarction, highlighting the limited available data and the need for future trials.
Why the study?
Do drug-eluting stents provide benefit over bare-metal stents in patients with ST-elevation acute myocardial infarction?
Do drug-eluting stents provide benefit over bare-metal stents in patients with ST-elevation acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
This review discusses the theoretical risks and benefits of drug-eluting stents for ST-elevation acute myocardial infarction and highlights the need for future randomized trials.
Since their introduction, drug-eluting stents have rapidly altered modern medicine's approach to coronary artery disease. Before the development of drug-eluting stents, standard bare-metal stents were plagued by in-stent restenosis, requiring repeat revascularization in as many as 15-20% of patients during the first 6-12 months following implantation [1]. The currently approved drug-eluting stents have dramatically reduced this complication by using a polymer-impregnated coating that elutes either paclitaxel or sirolimus to inhibit smooth muscle proliferation. The pivotal TAXUS-IV [2] and SIRIUS [3] trials compared drug-eluting stents with standard bare-metal stents and found rates of target vessel revascularization ranging from 3 to 4.1% in stable coronary artery disease patients - far lower than that had been seen previously with conventional standard bare-metal stents. After their approval in April 2003, drug-eluting stents use in clinical practice expanded rapidly. Within 9 months of their introduction, drug-eluting stents comprised 35% of all stent implantations in the United States [4]. In the last year at our own institution, drug-eluting stents comprised over 85% of all stents implanted. Despite their extensive use, data regarding the efficacy and safety of drug-eluting stents in certain clinical scenarios are limited. To date, the only published data supporting drug-eluting stents in ST[corrected]-elevation acute myocardial infarction come from the retrospective Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry [5] and the randomized, controlled single high-dose bolus tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent in myocardial infarction study [6]. In this chapter, we discuss the theoretical risks and benefits of drug-eluting stents for ST elevation acute myocardial infarction, the available data regarding their use, and the areas in which future studies are needed.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2006) conducted a review in ST-elevation acute myocardial infarction. Drug-eluting stents vs. Bare-metal stents was evaluated. This review discusses the theoretical risks and benefits of drug-eluting stents for ST-elevation acute myocardial infarction, highlighting the limited available data and the need for future trials.
Synapse has enriched 10 related papers. Consider them for comparative context: